This is an excerpt of the complete article - to download the complete PDF - CLICK HERE
Final quality control remains essential, but it is an expensive place to discover an error. By then, further materials, production time, laboratory capacity and release effort have already been committed. The outcome may be quarantine, investigation, rework or destruction. If the problem is not detected before release, the exposure can extend to patient or consumer harm, product recall, supply interruption, regulatory action, litigation and lasting damage to confidence in the manufacturer.
The dispensary is therefore not simply a preparation area. It is one of the points at which the intended product becomes the physical batch —and where a preventable error can become embedded in it.
The consequences are already on record
The following cases are cited to illustrate historical failure modes. They do not imply anything about the companies’ current systems or standards, and no single technology should be presented as capable of preventing every type of manufacturing failure.
At GSK’s former Cidra facility in Puerto Rico, the US Department of Justice reported that Avandamet tablets did not always contain the FDA-approved mix of active ingredients and could contain too much or too little of the therapeutically active component. The same case included longstanding product mix-ups involving different drug types or strengths. In 2010, subsidiary SB Pharmco agreed to plead guilty, with a resolution comprising a $150 million criminal fine and forfeiture and a $600 million civil settlement. The case shows how failures of formulation and material control can move beyond a batch deviation into major criminal and civil exposure.
This is an excerpt of the complete article - to download the complete PDF - CLICK HERE
